Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens
François Cholette, Rissa Fabia, Angela Harris, Hannah Ellis, Karla Cachero, Lukas Schroeder, Christine Mesa, Philip Lacap, Corey Arnold, Yannick Galipeau, Marc‐André Langlois, Karen Colwill, Anne‐Claude Gingras, Allison McGeer, Elizabeth Giles, Jacqueline Day, Carla Osiowy, Yves Durocher, Catherine Hankins, Bruce Mazer, Michael Drebot, John Kim
Abstract
= 90). Our findings suggest that several assays are suitable for serosurveillance (sensitivity >97% and specificity >98%). In contrast to other reports, we did not observe an improvement in performance using multiple antigen consensus-based rules to establish overall seropositivity. This may be due to our DBS panel which consisted of samples collected from convalescent COVID-19 patients with significant anti-spike, -receptor binding domain (RBD), and -nucleocapsid antibody titers. This study demonstrates that biological specimens collected as DBS coupled with one of several readily available assays are useful for large-scale COVID-19 serosurveillance.